Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
The benefits of different screening strategies and therapeutic interventions.
Obesity has many implications for injured workers, from being a catalyst for injuries to increasing healthcare costs and lengthening time away from work.
Comorbid obesity can complicate recovery, and new drugs create new pharmacy considerations.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
